Pulmonary Artery Involvement in Takayasu’s Arteritis

Learn more about:
Related Clinical Trial
A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK) Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis A Pilot Study in Severe Patients With Takayasu Arteritis. Efficiency of Methotrexate and Tofacitinib in Mild and Moderate Patients Drug-coated Balloon for Takayasu Arteritis Associated Renal Artery Stenosis The Registry Study of Takayasu Arteritis in East China Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases A Registry Study on Biomarkers of Takayasu’s Arteritis (ARSBTA) Infliximab Biosimilar in Takayasu’s Arteritis Exercise in Juvenile Takayasu Disease Pulmonary Artery Involvement in Takayasu’s Arteritis Anti-inflammatory Treatment for Inactive Takayasu Arteritis Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis Aerobic Capacity and Strength Exercise in Takayasu’s Arteritis Use of MRI and PET for Assessing Disease Activity in Takayasu’s Arteritis Impact and Utility of PET Versus Clinical Score for the Assessment of Inflammatory Activity in Takayasu Arteritis Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu’s Arteritis Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis Registration Study of Takayasu’s Arteritis in China Determining Disease Activity Biomarkers in Individuals With Takayasu’s Arteritis Takayasu Arteritis Activity Evaluation by Ultrafast Ultrasound Imaging China Takayasu Arteritis Registry (CTA Registry) Takayasu Arteritis Clinical Trial in China

Brief Title

Pulmonary Artery Involvement in Takayasu's Arteritis

Official Title

Pulmonary Artery Involvement in Takayasu's Arteritis: a Retrospective Study in China

Brief Summary

      The purpose of this study is to analyze the clinical manifestations, imaging features, and
      prognosis-related factors of pulmonary artery (PA) involvement in Takayasu's arteritis (TA),
      and to explore the early clinical features of PA involvement in TA patients.
    

Detailed Description

      Takayasu's arteritis patients with pulmonary artery involvement were enrolled into this
      study. The demographic information of the patients (age, sex, course of disease), symptoms at
      their admissions (cough, hemoptysis, dyspnea, palpitations, fever), laboratory examinations
      (blood lab routines, erythrocyte sedimentation rate, C-reactive protein), and imaging
      examinations (vascular ultrasonography, computed tomographic angiography, echocardiography,
      chest CT, CTPA, pulmonary perfusion imaging, pulmonary angiography, PET/CT) were collected by
      reviewing the cases. The prognostic information was collected by telephone follow-up. The
      follow-up end point was December 2015.
    


Study Type

Observational


Primary Outcome

Pulmonary Artery Systolic Blood Pressure


Condition

Takayasu Arteritis



Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

51

Start Date

January 1, 2014

Completion Date

December 31, 2015

Primary Completion Date

December 31, 2015

Eligibility Criteria

        Inclusion Criteria:

          -  1.Meet the diagnostic criteria of TA as defined by the American College of
             Rheumatology (ACR).

          -  2.PA involvement: meet at least one of three items: (1) at least one of computed
             tomographic pulmonary angiography (CTPA), pulmonary perfusion imaging, or pulmonary
             arteriography suggests thickening of vessel wall, stenosis, aneurysm, or occlusion;
             (2) 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT)
             suggests high intake of local radioactive material in pulmonary artery wall; (3)
             pulmonary artery systolic blood pressure is higher than 50 mmHg assessed by
             transthoracic echocardiography (defined as PAH), without left ventricular disease.

        Exclusion Criteria:

        -
      

Gender

All

Ages

14 Years - 67 Years

Accepts Healthy Volunteers

No

Contacts

Juhong Shi, M.D, , 

Location Countries

China

Location Countries

China

Administrative Informations


NCT ID

NCT03189602

Organization ID

PUMCH-Pulmonary arteritis


Responsible Party

Sponsor

Study Sponsor

Peking Union Medical College Hospital


Study Sponsor

Juhong Shi, M.D, Study Chair, Peking Union Medical College Hospital


Verification Date

June 2017